Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.50 |
| ▸ | FDPS | P14324 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARD | Q03181 | 5/20 | 0.44 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018949 | 1.00 | SMPD1 (0.50) | SMPD1FDPSCES2PPARGPPARD | |
| SCHEMBL1027737 | 1.00 | SMPD1 (0.50) | SMPD1FDPSCES2PPARGPPARD | |
| SCHEMBL20599006 | 1.00 | SMPD1 (0.50) | SMPD1FDPSCES2PPARGPPARD | |
| SCHEMBL287722 | 1.00 | SMPD1 (0.50) | SMPD1FDPSCES2PPARGPPARD | |
| SCHEMBL14931594 | 1.00 | SMPD1 (0.50) | SMPD1FDPSCES2PPARGPPARD | |
| SCHEMBL259016 | 0.98 | FDPS (0.48) | SMPD1FDPSCES2PPARGPPARD | |
| Propionic Acid SCHEMBL7632408 | 0.94 | SMPD1 (0.46) | SMPD1FDPSPPARGPPARDPPARA | |
| SCHEMBL288685 | 0.91 | FDPS (0.46) | SMPD1FDPSPPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL28391923 | 0.88 | FDPS (0.45) | SMPD1FDPSPPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL27328297 | 0.88 | FDPS (0.45) | SMPD1FDPSPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3103446-B1 | PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA | ZAKHAROV IVAN DMITRIEVICH (RU) | 2024-02-14 | — | — | EP | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3103446-B1 | PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA | ZAKHAROV IVAN DMITRIEVICH (RU) | 2024-02-14 | — | — | EP | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2023-05-23 | — | — | US | disclosed |
| EP-1419178-B1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | UNIV BERN (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | UNIVERSITY OF BERN (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1419178-A1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | University of Bern (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014158-A1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | UNIVERSITY OF BERN (CH) | 2003-02-20 | — | — | WO | disclosed |
| EP-1283216-A1 | Somatostatin analogues binding to all somatostatin receptor subtypes and their use | Mallinckrodt Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6420518-B1 | POLYPEPTIDES WITH AMINO ACID SEQUENCES | GENETECH, INC. | 2002-07-16 | — | — | US | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | SMPD1 3541/4885FDPS 1981/4885CES2 2349/4885 |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | SMPD1 982/4885FDPS 3340/4885CES2 951/4885 |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | SMPD1 982/4885FDPS 3340/4885CES2 951/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | SMPD1 3541/4885FDPS 1981/4885CES2 2349/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | SMPD1 1069/4885FDPS 3364/4885CES2 971/4885 |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | SSTR5, NPY5R, GLP1R | SMPD1 2165/4885FDPS 3241/4885CES2 2911/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | SMPD1 3541/4885FDPS 1981/4885CES2 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.